JCR Pharmaceuticals Co., Ltd. Wins Japan Orphan, Priority Review for Givinostat in DMD
JCR Pharmaceuticals received orphan drug designation and Priority Examination in Japan for givinostat for Duchenne muscular dystrophy and plans to file for marketing approval by end-2026.Material DetailsContext by AI AnalystThis is an early regulatory de-risking step following JCR’s 2025 exclusive…